reports
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expan...
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it received approximately $3.0 million in gross proceeds from the amendment and exercise of existing warrants. ...
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis A...
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, reaffirms its commitment to improving the lives of patients suffering from diabetic gastroparesis in light of the recent decision by the U.S. Food and Drug Administr...
Evoke Pharma to Participate in Gastroenterology and Hepatology Advance...
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that management will participate in the Gastroenterology and Hepatology Advanced Practice Providers Conference taking place from September 12 – 14, 2024 at the Gaylord National Resort Convention Center in National Ha...
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Invest...
Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place from September 9 – 11, 2024 at the Lotte New York Palace Hotel in New York City. Evoke’s presentation covering the recent positive com...
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills during Q2 75% year-over-year prescription fill increase; 32% growth compared to Q1 2024 Two abstracts submitted and accepted by the American College of Gastroenterology (ACG) focusing on use of GIMOTI in patients on GLP-1 analogs SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK),...
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, together with , a leading provider of global commercial services to the life science industry, joins the gastrop...
Evoke Pharma, Inc. Announces Reverse Stock Split
Evoke Pharma, Inc. Announces Reverse Stock Split SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its board of directors (Board) has approved a 1-for-12 reverse stock split of the company's common stock. The reverse stock split will become effective at 12:01 a.m. Eastern time on August 1, 2024. The company's common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Capital Marke...
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum ...
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced updates regarding their business and commercial growth strategy. With a determined focus to ensu...
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data ...
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference Evoke commercial booth located at site #737 SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disea...
Evoke Pharma Reports First Quarter 2024 Financial Results
Evoke Pharma Reports First Quarter 2024 Financial Results 114% year-over-year increase in net product sales70% prescriber growth in Q1 2024 compared to Q4 2023Growing sales metrics reaffirms company’s $14M net revenue guidance for 2024 SOLANA BEACH, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2024, and recent corporate devel...
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the E...
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m. ET. Moderated by Ya...
Evoke Pharma Announces Senior Leadership Transition with Promotion of ...
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons. Mr. D’Onofrio currently serves as President and Chief Op...
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Resul...
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024 SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and recen...
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on Ma...
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024 SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2023 on Thursday, March 14, 2024, after the market closes. Management will host a conference call and webcast with accompanying slides on Thursday, March 14, 2024, at 4:30 p.m. ET...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
Evoke Pharma Announces Closing of $7.5 Million Public Offering Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full SOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has closed an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 m...
Evoke Pharma Announces Pricing of Underwritten Public Offering of up t...
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million, that includes initial upfront funding of approximately $7.5 million, prior to deducting underwriti...
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent GIMOTI now holds four listed patents with coverage through 2029 SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly known as the ...
United States Patent and Trademark Office (USPTO) Grants Another Formu...
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI The Company Will Submit for FDA Orange-Book Listing in the Near Term SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Compa...
Evoke Pharma Reports Third Quarter 2023 Financial Results
Evoke Pharma Reports Third Quarter 2023 Financial Results 38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: EVOK), a specialty pharmaceutical company focus...
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrat...
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023 Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- , a specialty pharmaceutical company focused primarily on treatments for ga...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.